IHL-305

 
National Institutes of Health

Topic mentions per year

Topic mentions per year

2009-2015
012320092015

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2015
2015
IHL-305 is a PEGylated liposomal formulation of irinotecan (CPT-11). The objective of this study was to evaluate the factors… (More)
  • table 1
  • figure 2
  • figure 1
  • figure 3
  • table 2
Is this relevant?
2013
2013
To investigate pharmacokinetics (PK) of encapsulated CPT-11, released CPT-11 and the active metabolite SN-38 following… (More)
  • table 1
  • table 2
  • figure 2
  • figure 3
  • figure 4
Is this relevant?
2012
2012
The antitumor effect of IHL-305, a novel pegylated liposome containing irinotecan, was investigated in human… (More)
Is this relevant?
2012
2012
Advanced ovarian cancer is characterized by peritoneal metastasis and the accumulation of ascites. Peritoneal metastasis of… (More)
  • figure 1
  • figure 2
  • figure 3
  • figure 4
  • table 1
Is this relevant?
2012
2012
IHL-305 is a novel PEGylated liposome containing irinotecan. This study examined the safety profile and pharmacokinetics of IHL… (More)
  • table 1
  • table 2
  • table 3
  • figure 1
Is this relevant?
2009
2009
2547 Background: Irinotecan (CPT-11) is a prodrug of SN-38 that has antitumor activity in a wide range of solid tumors. IHL- 305… (More)
Is this relevant?